Advertisement

Topics

SERI LUGANO Company Profile

12:03 EDT 14th August 2018 | BioPortfolio


News Articles [7 Associated News Articles listed on BioPortfolio]

SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconus

Inventor of ParaCel Roberto Pinelli, MD released in 2011 his intellectual property rights to AVEDRO, Inc. The Switzerland Eye Research Institute has announced that the ...

NTU Singapore and SERI invent new scope to diagnose glaucoma

(Nanyang Technological University) A new 'pen camera' has been developed jointly by scientists from Nanyang Technological University, Singapore (NTU Singapore) and the Singapore Eye Research Institute...

Cristiano Ronaldo vstupuje do partnerstva so spoločnosťou Graphic India a VMS Communications ...

„Vždy som bol fanúšikom superhrdinov a možnosť spoluvytvárať nový animovaný seriál som hneď privítal,"dodal Cristiano Ronaldo. „Tak ako futbal spája kultúry a ľudí celého svet...

Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting

Latest Data on Lenvima (Lenvatinib) / Keytuda (Pembrolizumab) Combination Therapy to be Presented TOKYO, May 17, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a seri...

Cristiano Ronaldo představil nový animovaný seriál „STRIKER FORCE 7 vzniklý v ...

„ Vždy jsem byl fanouškem superhrdinů a jsem nadšený, že mohu pomoci vytvořit tuto novou animovanou sérii,"uvedl  Cristiano Ronaldo. „Stejně jako fotbal spojuje Read more...

FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting

Lugano, Switzerland April 20, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has appr...

Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

Helsinn Healthcare SA / Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer thera...

Drugs and Medications [0 Results]

None

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

The clinical manifestation, survival outcome and predictive prognostic factors of 137 patients with primary gastrointestinal lymphoma (PGIL): Strobe compliant.

This retrospective study aimed to investigate clinical characteristics and prognostic factors in patients with primary gastrointestinal lymphoma (PGIL) of Chinese population.From January 2001 to Decem...

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), ...

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.

The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading expert...

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support and Repair in Breast Reconstruction

Prospective, single center, postmarket clinical study to obtain clinical experience with the use of SERI® Surgical Scaffold for soft tissue support and repair in breast reconstruction.

Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and C...

Prospective, Randomized, Controlled, Clinical Study on Tolerability and Efficacy of hMG-IBSA

Purpose of the study is the evaluation of the tolerability (both local and systemic) and the clinical efficacy (in terms oocytes recovered) of subcutaneously versus intramuscularly adminis...

A Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

The study is to evaluate the efficacy of BGB-A317 assessed by Independent Review Committee (IRC) in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Ov...

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

The primary objective of the phase Ib of the study is to determine the recommended phase 2 dose (RP2D) for entospletinib (ENTO) in patients treated with R-CHOP. The primary objective of t...

Companies [3 Associated Companies listed on BioPortfolio]

SERI LUGANO

Helsinn Healthcare SA

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in USA and Ireland. Helsinn's unique business model is focused on the licensing of phar...

Helsinn Group and DARA BioSciences, Inc.

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business mo...

More Information about "SERI LUGANO" on BioPortfolio

We have published hundreds of SERI LUGANO news stories on BioPortfolio along with dozens of SERI LUGANO Clinical Trials and PubMed Articles about SERI LUGANO for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SERI LUGANO Companies in our database. You can also find out about relevant SERI LUGANO Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record